What question did this study set out to answer?

This analysis aims to explore the relationship between vorasidenib treatment, seizure rates, and tumor volume in mIDH1/2 glioma patients.

June 13, 2026Neurology

Exploratory Analyses from the Phase Three INDIGO Study Suggest Potential Mechanism of Seizure Control Through Tumor Volume Reduction Under Treatment With Vorasidenib (S28.002)

View Full Paper

Ask AI

Bookmark

This analysis aims to explore the relationship between vorasidenib treatment, seizure rates, and tumor volume in mIDH1/2 glioma patients.
Conducted exploratory analyses from the Phase Three INDIGO Study
Assessed relationships between vorasidenib, seizure rates, tumor volume, and seizure activity in patients with mIDH1/2 glioma
Identified reductions in tumor volume correlating with improved seizure control
Observed a potential mechanism linking tumor volume reduction and lower seizure rates in patients

Implication

Exploratory analyses investigate the relationship between tumor volume and seizure control in mIDH1/2 glioma, suggesting implications for treatment.

Abstract

We investigated potential relationships between vorasidenib/seizure rate and tumor volume/seizure activity in patients with isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Peters et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf34dfaef96ed7f055c9e https://doi.org/10.1212/wnl.0000000000216249

View Full Paper

Ask AI

Bookmark

Implication

Exploratory analyses investigate the relationship between tumor volume and seizure control in mIDH1/2 glioma, suggesting implications for treatment.

Abstract

We investigated potential relationships between vorasidenib/seizure rate and tumor volume/seizure activity in patients with isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma.

Exploratory Analyses from the Phase Three INDIGO Study Suggest Potential Mechanism of Seizure Control Through Tumor Volume Reduction Under Treatment With Vorasidenib (S28.002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Exploratory Analyses from the Phase Three INDIGO Study Suggest Potential Mechanism of Seizure Control Through Tumor Volume Reduction Under Treatment With Vorasidenib (S28.002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading